Cargando…

Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer

PURPOSE: Tumor purity is defined as the proportion of cancer cells in the tumor tissue. The impact of tumor purity on colon cancer (CC) prognosis, genetic profile, and microenvironment has not been thoroughly accessed. MATERIALS AND METHODS: Clinical and transcriptomic data from three public dataset...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Yihao, Feng, Qingyang, Zheng, Peng, Yang, Liangliang, Liu, Tianyu, Xu, Yuqiu, Zhu, Dexiang, Chang, Wenju, Ji, Meiling, Ren, Li, Wei, Ye, He, Guodong, Xu, Jianmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149864/
https://www.ncbi.nlm.nih.gov/pubmed/30271205
http://dx.doi.org/10.2147/CMAR.S171855
_version_ 1783356885711192064
author Mao, Yihao
Feng, Qingyang
Zheng, Peng
Yang, Liangliang
Liu, Tianyu
Xu, Yuqiu
Zhu, Dexiang
Chang, Wenju
Ji, Meiling
Ren, Li
Wei, Ye
He, Guodong
Xu, Jianmin
author_facet Mao, Yihao
Feng, Qingyang
Zheng, Peng
Yang, Liangliang
Liu, Tianyu
Xu, Yuqiu
Zhu, Dexiang
Chang, Wenju
Ji, Meiling
Ren, Li
Wei, Ye
He, Guodong
Xu, Jianmin
author_sort Mao, Yihao
collection PubMed
description PURPOSE: Tumor purity is defined as the proportion of cancer cells in the tumor tissue. The impact of tumor purity on colon cancer (CC) prognosis, genetic profile, and microenvironment has not been thoroughly accessed. MATERIALS AND METHODS: Clinical and transcriptomic data from three public datasets, GSE17536/17537, GSE39582, and TCGA, were retrospectively collected (n=1,248). Tumor purity of each sample was inferred by a computational method based on transcriptomic data. Survival-related analyses were performed on microarray dataset containing GSE17536/17537 and GSE39582 (n=794), whereas TCGA dataset was utilized for subsequent genomic analysis (n=454). RESULTS: Right-sided CC patients showed a significantly lower tumor purity. Low purity CC conferred worse survival, and tumor purity was identified as an independent prognostic factor. Moreover, high tumor purity CC patients benefited more from adjuvant chemotherapy. Subsequent genomic analysis found that the mutation burden was negatively associated with tumor purity, with only APC and KRAS significantly more mutated in high purity CC. However, no somatic copy number alteration event was correlated with tumor purity. Furthermore, immune-related pathways and immunotherapy-associated markers (programmed cell death protein 1 [PD-1], programmed death-ligand 1 [PD-L1], cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], Lymphocyte-activation gene 3 [LAG-3] and T-cell immunoglobulin and mucin-domain containing-3 [TIM-3]) were highly enriched in low purity samples. Notably, the relative proportion of M2 macrophages and neutrophils, which indicated worse survival in CC, was negatively associated with tumor purity. CONCLUSION: Tumor purity exhibited potential value for CC prognostic stratification as well as adjuvant chemotherapy benefit prediction. The relative worse survival in low purity CC may attribute to higher mutation frequency in key pathways and purity-related microenvironmental changing.
format Online
Article
Text
id pubmed-6149864
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61498642018-09-28 Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer Mao, Yihao Feng, Qingyang Zheng, Peng Yang, Liangliang Liu, Tianyu Xu, Yuqiu Zhu, Dexiang Chang, Wenju Ji, Meiling Ren, Li Wei, Ye He, Guodong Xu, Jianmin Cancer Manag Res Original Research PURPOSE: Tumor purity is defined as the proportion of cancer cells in the tumor tissue. The impact of tumor purity on colon cancer (CC) prognosis, genetic profile, and microenvironment has not been thoroughly accessed. MATERIALS AND METHODS: Clinical and transcriptomic data from three public datasets, GSE17536/17537, GSE39582, and TCGA, were retrospectively collected (n=1,248). Tumor purity of each sample was inferred by a computational method based on transcriptomic data. Survival-related analyses were performed on microarray dataset containing GSE17536/17537 and GSE39582 (n=794), whereas TCGA dataset was utilized for subsequent genomic analysis (n=454). RESULTS: Right-sided CC patients showed a significantly lower tumor purity. Low purity CC conferred worse survival, and tumor purity was identified as an independent prognostic factor. Moreover, high tumor purity CC patients benefited more from adjuvant chemotherapy. Subsequent genomic analysis found that the mutation burden was negatively associated with tumor purity, with only APC and KRAS significantly more mutated in high purity CC. However, no somatic copy number alteration event was correlated with tumor purity. Furthermore, immune-related pathways and immunotherapy-associated markers (programmed cell death protein 1 [PD-1], programmed death-ligand 1 [PD-L1], cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], Lymphocyte-activation gene 3 [LAG-3] and T-cell immunoglobulin and mucin-domain containing-3 [TIM-3]) were highly enriched in low purity samples. Notably, the relative proportion of M2 macrophages and neutrophils, which indicated worse survival in CC, was negatively associated with tumor purity. CONCLUSION: Tumor purity exhibited potential value for CC prognostic stratification as well as adjuvant chemotherapy benefit prediction. The relative worse survival in low purity CC may attribute to higher mutation frequency in key pathways and purity-related microenvironmental changing. Dove Medical Press 2018-09-17 /pmc/articles/PMC6149864/ /pubmed/30271205 http://dx.doi.org/10.2147/CMAR.S171855 Text en © 2018 Mao et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Mao, Yihao
Feng, Qingyang
Zheng, Peng
Yang, Liangliang
Liu, Tianyu
Xu, Yuqiu
Zhu, Dexiang
Chang, Wenju
Ji, Meiling
Ren, Li
Wei, Ye
He, Guodong
Xu, Jianmin
Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer
title Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer
title_full Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer
title_fullStr Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer
title_full_unstemmed Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer
title_short Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer
title_sort low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149864/
https://www.ncbi.nlm.nih.gov/pubmed/30271205
http://dx.doi.org/10.2147/CMAR.S171855
work_keys_str_mv AT maoyihao lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer
AT fengqingyang lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer
AT zhengpeng lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer
AT yangliangliang lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer
AT liutianyu lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer
AT xuyuqiu lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer
AT zhudexiang lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer
AT changwenju lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer
AT jimeiling lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer
AT renli lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer
AT weiye lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer
AT heguodong lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer
AT xujianmin lowtumorpurityisassociatedwithpoorprognosisheavymutationburdenandintenseimmunephenotypeincoloncancer